NCT01752920 2023-06-05Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic AlterationsBasilea PharmaceuticaPhase 1/2 Completed119 enrolled 15 charts